Vistogard
(uridine triacetate)PreclinicalSmall molecule
Vistogard is one of 50 small molecule programs targeting Toxicity. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
49
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
62 competitors in Toxicity
#DrugCompanyPhaseTrials
1Norvir
AbbVieApproved
Oncovin
Eli LillyApproved
Aldactone
PfizerApproved
Zyvox
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Rayos
RRoxane Laboratories
Approved
Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Sep 4, 2015
XURIDEN
NDA NDA208169
Dec 11, 2015
VISTOGARD
NDA NDA208159
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for uridine triacetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBTG International Inc.
Patent Landscape[5]
Patent Cliff
Aug 17, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7776838Aug 17, 2027